Skip to main content

First Light Diagnostics Raises $8.25M

NEW YORK (360Dx) – First Light Diagnostics announced today it has closed an oversubscribed Series A-2 financing round that raised $8.25 million.

The financing will go toward continued development of its MultiPath technology to rapidly identify hospital infections and determine their antibiotic susceptibility. The company expects to commercialize the technology in early 2020, it said.

New investors Think.Health Ventures, 10X Group, and Beacon Angels participated in the financing round, which also included new individual investors and current shareholders, including LRV Health and Life Science Angels.

According to First Light's website, the MultiPath platform combines non-magnified digital imaging with specific targeting, providing multiplexing capability for the detection of bacteria, fungi, viruses, toxins, biomarkers, and diagnostically relevant human cells.

Based in Chelmsford, Massachusetts, the company recently changed its name from First Light Biosciences to reflect the company's evolution from development to commercialization of diagnostic solutions.